Detalhe da pesquisa
1.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
N Engl J Med
; 386(18): 1687-1699, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35334197
2.
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
Br J Dermatol
; 188(2): 218-227, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763878
3.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
J Am Acad Dermatol
; 85(4): 847-853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090959
4.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
J Am Acad Dermatol
; 85(1): 62-70, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600915
5.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
J Dermatolog Treat
; 34(1): 2161812, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546346
6.
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
Am J Clin Dermatol
; 22(3): 395-405, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826132
7.
Wound-healing defect of CD18(-/-) mice due to a decrease in TGF-beta1 and myofibroblast differentiation.
EMBO J
; 24(19): 3400-10, 2005 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-16148944